GENFIT

About GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases characterized by high unmet medical needs. With over two decades of scientific heritage, GENFIT focuses on the discovery and development of drugs targeting liver diseases, boasting a diversified pipeline of innovative therapeutic and diagnostic solutions. The company is a world leader in Acute-on-Chronic Liver Failure (ACLF) and associated medical complications.

Products & Services

VS-01-ACLF:A therapeutic solution in development for Acute-on-Chronic Liver Failure (ACLF).

NTZ:A therapeutic asset for ACLF, based on differentiated mechanisms of action.

SRT-015:A program targeting ACLF with complementary pathways.

CLM-022:A development asset for ACLF.

VS-02-HE:A therapeutic solution for Hepatic Encephalopathy (HE), a common complication of ACLF.

GNS561 in CCA:A program targeting Cholangiocarcinoma (CCA), a life-threatening indication.

VS-01-HAC in UCD/OA:A therapeutic solution for Urea Cycle Disorders (UCD) and Organic Acidemias (OA).

Diagnostics for NASH/MASH and Ammonia:A diagnostic franchise focused on Nonalcoholic Steatohepatitis (NASH)/Metabolic dysfunction-associated steatohepatitis (MASH) and ammonia detection.

Elafibranor for PBC:A drug evaluated in a Phase 3 trial for Primary Biliary Cholangitis (PBC), now managed by Ipsen for regulatory and commercialization efforts.

Specialties

Liver Diseases Acute-on-Chronic Liver Failure (ACLF) Hepatic Encephalopathy (HE) Cholangiocarcinoma (CCA) Urea Cycle Disorders (UCD) Organic Acidemias (OA) Diagnostics for NASH/MASH Clinical Development Data Science Regulatory Affairs Market Access

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Royalty Financing T: - FT: Royalty Financing	A: 203500000 MR: - FA: up to €185 million FAN: 203500000	D: 2025-03-20 FD: 2025-03-20	1 investors
2	RT: Royalty Financing T: - FT: Royalty Financing	A: 139000000 MR: - FA: €130 million FAN: 139000000	D: 2025-03-10 FD: 2025-03-10	1 investors

Royalty Financing Latest

2025-03-20

$203.5M

1 investor (Pro only)

Royalty Financing 2025-03-10

$139.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jean-François Mouney

Chairman of the Board of Directors

N

Nguengang Wakap S

N

Nguengang Wakap S.

S

S. Nguengang Wakap

View 1 more team members with Pro

Unlock Full Team Directory

Recent News

GENFIT Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised